Rofecoxib, a new cyclooxygenase 2 inhibitor, shows sustained efficacy, comparable with other nonsteroidal anti-inflammatory drugs: A 6-week and a 1-year trial in patients with osteoarthritis

Archives of Family Medicine

Volumn 9, Issue 10, 2000, Pages 1124-1134

  Saag, K ^a   Van der Heijde, D ^a   Fisher, C ^a   Samara, A ^a   DeTora, L ^a   Bolognese, J ^a   Sperling, R ^a   Daniels, B ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; IBUPROFEN; NONSTEROID ANTIINFLAMMATORY AGENT; ROFECOXIB;

ADULT; ANTIINFLAMMATORY ACTIVITY; ARTHRITIS; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; MAJOR CLINICAL STUDY; MALE; OSTEOARTHRITIS; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 0034546509     PISSN: 10633987     EISSN: None     Source Type: Journal    
DOI: 10.1001/archfami.9.10.1124     Document Type: Article

References (34)

1. Prevalence and impact of arthritis among women - United States, 1989-1991
2. Osteoarthritis and related disorders: Epidemiology
3. Therapeutic strategies distinguish community based primary care physicians from rheumatologists in the management of osteoarthritis
4. Osteoarthritis and related disorders: Pathology
5. Osteoarthritis and related disorders: Clinical features and diagnostic problems
6. Osteoarthritis
7. Bone mineral density and risk of incident and progressive radiographic knee osteoarthritis in women: The Framingham Study
8. Development of criteria for the classification and reporting of osteoarthritis: Classification of osteoarthritis of the knee
9. Osteoarthritis
10. Management of osteoarthritis
11. Osteoarthritis and related disorders: The assessment of process and outcome in osteoarthritis
12. The epidemiology of osteoarthritis
13. Osteoarthritis and related disorders: Management of limb joint osteoarthritis
14. Guidelines for the medical management of osteoarthritis, part I: Osteoarthritis of the hip
15. Guidelines for the medical management of osteoarthritis, part II: Osteoarthritis of the knee
16. Utilization of nonsteroidal anti-inflammatory drugs
17. NSAID gastropathy: The second most deadly rheumatic disease? Epidemiology and risk appraisal
18. Nonsteroidal anti-inflammatory drug-associated gastropathy: Incidence and risk factor models
19. Gastrointestinal toxicity of nonsteroidal anti-inflammatory drugs
20. COX-1 and COX-2: Toward the development of more selective NSAIDs
21. Gastrointestinal toxicity of newer NSAIDs
22. Osteoarthritis antirheumatic drug trials, III: Setting the delta for clinical trials - Results of a consensus development (Delphi) exercise
23. Recommendations for a core set of outcome measures for future phase III clinical trials in knee, hip, and hand osteoarthritis: Consensus development at OMERACT III
24. The American College of Rheumatology 1991 revised criteria for the classification of global functional status in rheumatoid arthritis
25. Design and conduct of clinical trials in patients with osteoarthritis: Preliminary recommendations from a task force of the Osteoarthritis Research Society
26. Cox-2 specific inhibition with rofecoxib does not increase intestinal permeability in healthy subjects: A double-blind, crossover study comparing rofecoxib with placebo and indomethacin
27. Comparative activity of rofecoxib (MK-0966, VIOXX), meloxicam, diclofenac, buprofen and naproxen on COX-2 vs COX-1 in healthy female volunteers
28. Preclinical biological profile of rofecoxib (vioxx, mk-0966): A potent, orally active and highly selective cox-2 inhibitor
29. Rofecoxib [Vioxx, MK-0966; 4-(4′-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: A potent and orally active cyclooxygenase-2 inhibitor: Pharmacological and biochemical profiles
30. The discovery of rofecoxib, [MK 966, Vioxx,4-(4′-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2-inhibitor
31. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs
32. COX-1 and COX-2 tissue expression: Implications and predictions
33. Nonsteroidal anti-inflammatory drugs: Effects on kidney function